MedTrace Logo

Corticosteroids in Severe COVID-19(ASAP-C Study)

NCT04648410 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-07-27

No results posted yet for this study

Summary

Administration of systemic corticosteroids for patients with severe forms of severe acute respiratory syndrome(SARS-Co-2) infection are recommended by several guidelines. In the very beginning of SARS-Co-2 pandemic the early recommendation by professional organization was against routine use of corticosteroids for patients with coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS), despite previous data and clinical practice for patients with refractory or severe form of ARDS.

Conditions

  • Severe COVID-19

Interventions

OTHER

questionnaire

Members of European Society of Intensive Care will obtain an electronic survey considering their routine clinical practice regarding the administration of systemic corticosteroids among patients with COVID-19 ARDS

Sponsors & Collaborators

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Jan Malaska, MD., Ph.D · University Hospital Brno

Eligibility

Min Age
28 Days
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2023-09-30
Completion
2023-12-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04648410 on ClinicalTrials.gov